{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:33:18Z","timestamp":1793370798797,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018583","name":"University of Vermont Larner College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018583","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010941","name":"University of Vermont","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinme.2026.100655","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T06:20:52Z","timestamp":1791786052000},"page":"100655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The current landscape of neuro-oncology clinical trials"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5638-6048","authenticated-orcid":false,"given":"Neelia E.","family":"Abadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8634-0925","authenticated-orcid":false,"given":"Oluwatosin O.","family":"Akintola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clinme.2026.100655_bib1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.clinme.2026.100655_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clinme.2026.100655_bib3","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clinme.2026.100655_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.nec.2020.12.003","article-title":"The current landscape of immune checkpoint blockade in glioblastoma","volume":"32","author":"Akintola","year":"2021","journal-title":"Neurosurg Clin N Am"},{"issue":"1","key":"10.1016\/j.clinme.2026.100655_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11060-024-04846-5","article-title":"Clinical trial design for novel targeted agents in neuro-oncology","volume":"171","author":"Lim-Fat","year":"2025","journal-title":"J Neuro-Oncol"},{"issue":"4","key":"10.1016\/j.clinme.2026.100655_bib6","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1078-0432.CCR-21-2750","article-title":"Glioblastoma clinical trials: current landscape and opportunities for improvement","volume":"28","author":"Bagley","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.clinme.2026.100655_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers16244148","article-title":"Immune checkpoint inhibitors in glioblastoma IDHwt treatment: a systematic review","volume":"16","author":"Baskaran","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.clinme.2026.100655_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11060-025-05315-3","article-title":"Immunotherapy and targeted therapy for high grade gliomas: current and future directions","volume":"176","author":"Hsueh","year":"2025","journal-title":"J Neuro-Oncol"},{"issue":"11","key":"10.1016\/j.clinme.2026.100655_bib9","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jamaneurol.2014.1701","article-title":"Emerging therapies for glioblastoma","volume":"71","author":"Thomas","year":"2014","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.clinme.2026.100655_bib10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clinme.2026.100655_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11910-026-01484-4","article-title":"Recent advances in targeted therapies for adult gliomas","volume":"26","author":"Lasica","year":"2026","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"10.1016\/j.clinme.2026.100655_bib12","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.ijrobp.2020.07.2109","article-title":"Radiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus standard-dose (SD) RT with temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): preliminary results of NRG Oncology BN001","volume":"108","author":"Gondi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clinme.2026.100655_bib13","article-title":"Signal-seeking P2R trial of proton or IMRT dose intensification in GBM: NRG-BN001","volume":"123","author":"Mehta","year":"2025","journal-title":"Int J Radiat Oncol Biology Phys"},{"issue":"6","key":"10.1016\/j.clinme.2026.100655_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/brainsci12060787","article-title":"Neurosurgical clinical trials for glioblastoma: current and future directions","volume":"12","author":"Shah","year":"2022","journal-title":"Brain Sci"},{"issue":"11","key":"10.1016\/j.clinme.2026.100655_bib15","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1093\/neuonc\/noaf177","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.clinme.2026.100655_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.06.2172","article-title":"Integrating collagen tile brachytherapy with external beam radiation and temozolomide for newly diagnosed glioblastoma: a preliminary report from a feasibility trial","volume":"123","author":"Peach","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.clinme.2026.100655_bib17","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/S2589-7500(22)00144-3","article-title":"Radiomics in neuro-oncological clinical trials","volume":"4","author":"Lohmann","year":"2022","journal-title":"Lancet Digit Health"},{"issue":"10457","key":"10.1016\/j.clinme.2026.100655_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(24)01295-9","article-title":"Bayesian statistics for clinical research","volume":"404","author":"Goligher","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clinme.2026.100655_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211826001041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211826001041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:56:13Z","timestamp":1793368573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211826001041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1470211826001041"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100655","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The current landscape of neuro-oncology clinical trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100655"}}